本文選題：經(jīng)皮冠狀動脈介入 + 高齡�。� 參考：《浙江大學(xué)》2017年碩士論文

【摘要】：目的了解高齡患者PCI術(shù)后患者生活質(zhì)量和焦慮抑郁情緒情況;探討益心舒膠囊對經(jīng)皮冠狀動脈介入(PCI)術(shù)后高齡患者血管功能和生活質(zhì)量的影響,評價(jià)益心舒膠囊對PCI術(shù)后患者的焦慮、抑郁情緒和生活質(zhì)量改善的有效性和安全性。方法前瞻性收集PCI術(shù)后高齡患者80例,將患者隨機(jī)分為研究組和對照組,每組各40例,所有患者均給予常規(guī)治療,在此基礎(chǔ)上,研究組給予益心舒膠囊口服。主要觀察指標(biāo):心血管不良事件(再發(fā)胸痛、再發(fā)心梗、再次血運(yùn)重建和死亡)、射血分?jǐn)?shù)(LVEF)、健康相關(guān)生存質(zhì)量(SF-36)、焦慮自我評分(SAS)及抑郁自我評分(SDS)。結(jié)果兩組患者心血管不良事件發(fā)生率無統(tǒng)計(jì)學(xué)意義(P0.05)。治療前兩組患者射血分?jǐn)?shù)、SAS和SDS等差異無統(tǒng)計(jì)學(xué)意義(P0.05)。治療后12月時研究組射血分?jǐn)?shù)顯著高于對照組(0.60±0.08 vs.0.55±0.09,P=0.013);治療后12月時研究組患者健康相關(guān)生存質(zhì)量(SF-36)顯著高于對照組(70.45±8.83vs.66.00±7.92,P=0.020);SAS評分顯著降低(32.87±6.90 vs.41.07±8.32,P=0.000);SDS 評分顯著降低(32.32±6.65 vs.38.02±11.07,P=0.021)。結(jié)論P(yáng)CI術(shù)后高齡患者廣泛存在焦慮抑郁癥狀,在臨床應(yīng)用中,早發(fā)現(xiàn)、早治療將有助于患者避免焦慮抑郁情緒的影響,改善患者的生活質(zhì)量;益心舒膠囊能有效地改善PCI術(shù)后高齡患者的癥狀,有利于減輕他們的心理壓力,減少或消除焦慮抑郁情緒,有助于改善PCI術(shù)后高齡患者血管功能、生活質(zhì)量和心理健康狀況,目前無嚴(yán)重不良反應(yīng),是一個安全有效的藥物。
[Abstract]:Objective to investigate the effect of Yixinshu capsule on vascular function and quality of life after percutaneous coronary intervention in elderly patients with PCI. To evaluate the efficacy and safety of Yixinshu capsule in improving anxiety, depression and quality of life after PCI. Methods 80 elderly patients after PCI were randomly divided into study group (n = 40) and control group (n = 40). All patients were given routine therapy. On this basis, the study group was given Yixinshu capsule orally. Main outcome measures: adverse cardiovascular events (recurrent chest pain, recurrent myocardial infarction, re-revascularization and death, ejection fraction, health-related quality of life (SF-36), anxiety self-score (SAS) and depression self-score (SDS). Results there was no significant difference in the incidence of cardiovascular adverse events between the two groups (P 0.05). There was no significant difference in ejection fraction SAS and SDS between the two groups before treatment (P 0.05). At 12 months after treatment, the ejection fraction in the study group was significantly higher than that in the control group (0.60 鹵0.08 vs.0.55 鹵0.09 vs.0.55 鹵0.013) and the health-related quality of life (SF-36) in the study group was significantly higher than that in the control group (70.45 鹵7.92 vs.41.07 鹵7.92 vs.41.07 鹵8.32 鹵6.90 vs.41.07 鹵8.32 鹵6.65 vs.38.02 鹵11.07P0.021). Conclusion the symptoms of anxiety and depression exist widely in the elderly patients after PCI. In clinical application, early treatment will help the patients avoid the influence of anxiety and depression and improve their quality of life. Yixinshu capsule can effectively improve the symptoms of the elderly patients after PCI, reduce their psychological pressure, reduce or eliminate anxiety and depression, and help to improve the vascular function, quality of life and mental health status of the elderly patients after PCI. At present, there is no serious adverse reaction, is a safe and effective drug.
【學(xué)位授予單位】：浙江大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2017
【分類號】：R541.4
，

本文編號：1920231